Idiopathic REM sleep behavior disorder (IRBD) is a REM sleep parasomnia comprising unpleasant dreams, dream-enacting behaviors, and loss of muscle atonia during REM sleep. Longitudinal studies have demonstrated that because most patients with IRBD develop with time Parkinson disease (PD) and other synucleinopathies including dementia with Lewy bodies (DLB) or multiple system atrophy (MSA), IRBD represents a prodromal stage of these diseases.1 In PD, 5%–10% of cases are caused by nonfrequent mendelian mutations segregating with disease in pedigrees, but the vast majority of cases are sporadic. Unbiased genome-wide association studies in sporadic PD (sPD) have shown that single nucleotide polymorphisms (SNPs) in the α-synuclein (SNCA) and microtubule-associated protein tau (MAPT) genes modulate disease susceptibility.2 Given that IRBD often antedates sPD and that, akin to PD, familial clustering of IRBD is rare, we hypothesized that genetically shared variation at SNCA and MAPT may influence disease susceptibility to both conditions. Accordingly, we genotyped PD-associated genetic variants in SNCA and MAPT in a cohort of Spanish patients with IRBD.
Methods.
The SNPs rs356219 (A/G) in SNCA and rs1800547 (H1/H2) in MAPT have been consistently associated with sPD in the Spanish population.3,4 Here, we genotyped these markers in a Spanish Caucasian sample of 121 patients with IRBD and 175 healthy controls. This population was studied in a previous report.5 The IRBD group was recruited at the Multidisciplinary Sleep Unit of the Hospital Clínic de Barcelona, had a polysomnography-confirmed diagnosis, and consisted of 21/100 women/men (17.4/82.6%), with age at IRBD onset of 68.3 ± 6.2 years and age at sample collection of 71.2 ± 6.4 years. Patients fulfilled the diagnosis of IRBD and were free of parkinsonism, mild cognitive impairment, and dementia at the time of sample collection. After 6.8 ± 4.1 years of follow-up from IRBD diagnosis, 38 patients (31.4%) were clinically diagnosed with a synucleinopathy (DLB in 19 patients, PD in 18, and MSA in 1). Sex-, age-, and demographic-matched controls were recruited at the Multidisciplinary Sleep Unit of the Hospital Clínic de Barcelona (n = 45) and the Clínica Universitaria de Navarra (n = 129), and consisted of 21/154 women/men (13.6/86.4%) with age at sample collection of 71.7 ± 6.4 years. DNA was extracted from the peripheral blood using standard procedures. Genotyping was performed using the predesigned TaqMan assays C-1020193-10 (SNCA rs356219) and C-7563692-10 (MAPT rs1800547) in a StepOnePlus Real-time PCR System (Applied Biosystems, Foster City, CA). Allelic and genotypic frequencies were compared using SNPstats software (bioinfo.iconcologia.net/SNPstats).
Standard protocol approvals, registrations, and patient consents.
Samples were collected after patient's signed consent, and the local ethics committee approved the study.
Results.
We found no allelic or genotypic distribution differences of the SNCA marker rs356219 in patients with IRBD and in controls. However, we found an association of the MAPT polymorphism rs1800547 with IRBD. More specifically, we found that the frequency of the MAPT H2/H2 genotype which is protective for PD3,4 was underrepresented in our patients with IRBD. This association held statistically significant after adjusting for sex and age as covariates (odds ratio = 0.16; 95% confidence interval = 0.04–0.69; p = 0.002; table). Moreover, we observed that MAPT genotypes in patients with IRBD, but not in controls, were not in the Hardy-Weinberg equilibrium (p = 0.049), a finding which is consistent with previous observations for disease-linked loci in disease-affected individuals.6
Distribution of genotypic frequencies of SNCA and MAPT polymorphisms in patients with IRBD (n = 121) and sex- and age-matched healthy controls (n = 175)
Discussion.
We found that the MAPT marker rs1800547 is associated with IRBD. Consistently, we detected that the H2 variant which is protective for PD was underrepresented in our patients with IRBD. On the contrary, we did not find an association of the SNCA polymorphism rs356219 with IRBD. Altogether, these results are in agreement with another IRBD study reporting association for MAPT but not for SNCA polymorphisms.7 Yet, markers in both studies were different. These data raise the question whether IRBD shares with PD the same genetic risk factors or whether, alternatively, IRBD represents a specific endophenotype of PD with only certain genetic risk factors shared in common by both conditions. The later might be a plausible explanation because, although IRBD is considered a prodrome of sPD, not all patients with sPD develop RBD prior to parkinsonism. Supporting this view, we have recently reported that pathogenic mutations in the leucine-rich repeat kinase 2 gene (LRRK2), which are the most frequent genetic cause of PD, are absent in our IRBD cohort.5 One limitation of our study is the reduced number of patients with IRBD. Thus, future studies in larger cohorts are warranted to validate the association of MAPT with IRBD and also to further elucidate whether or not SNCA polymorphisms play a role in disease. We found that one polymorphism in MAPT which is associated with PD also modulates the propensity to IRBD. These results point toward an at least in part overlapping genetic susceptibility to both conditions in our Spanish population.
Acknowledgments
Acknowledgment: The authors thank the patients and their relatives who participated in the study. This study was conducted at the Centre de Recerca Biomèdica Cellex, Barcelona, Spain. The authors also thank the CERCA from the Generalitat de Catalunya and the European FEDER Programmes to IDIBAPS.
Footnotes
↵* These authors contributed equally to this work.
Author contributions: R.F.-S., A.I., and M.E. codirected the study and wrote the first draft of the manuscript. A.I, C.G, P.P., M.S., E.T., and J.S. diagnosed and followed up the patients, and recruited the controls. R.F.-S., M.F., P.P., and M.E. performed the genotyping. All authors interpreted the data and revised the manuscript.
Study funding: This work was supported by funds from the Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED) to the Movement Disorders Unit of the Neurology Service from the Hospital Clínic de Barcelona (grant PRI-16-207 to R.F.-S., A.I., C.G, M.S., M.F., E.T., J.S., and M.E.), and from the Spanish Ministry of Economy and Competitivity (MINECO) (grant SAF2013-47939-R to P.P.). R.F.-S. was supported by a Marie Skłodowska-Curie contract of the European Commission (EC) and Juan-de-la-Cierva contract of the Spanish Ministry of Economy and Competitiveness (MINECO), and M.E. by a Miguel Servet contract of the Instituto de Salud Carlos III (ISCIII).
Disclosure: Dr. Fernández-Santiago, Dr. Iranzo, Dr. Gaig, Ms. Serradell, Mr. Fernández, and Dr. Pastor report no disclosures. Dr. Tolosa has received speaker honoraria from UCB, Boeringer Ingelheim, Novartis, Abbot, Medtronic, Solvay, GSK, and Teva; has served on the editorial board of Neurological Sciences; holds a patent for Method for the subclassification of patients suffering from Parkinson disease; and has been a consultant for the Michael J. Fox Foundation for Parkinson's Disease, Novartis, UCB, Abbot, and Teva. Dr. Santamaría has received research support from Fundació La Marató TV3. Dr. Ezquerra reports no disclosures. Go to Neurology.org/ng for full disclosure forms. The Article Processing Charge was paid by CIBERNED.
- Received September 16, 2016.
- Accepted in final form October 28, 2016.
- Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
